TY - JOUR
T1 - Diet and Health-related Quality of Life Among Men on Active Surveillance for Early-stage Prostate Cancer
T2 - The Men's Eating and Living Study (Cancer and Leukemia Group 70807 [Alliance])
AU - Kellogg Parsons, J.
AU - Zahrieh, David
AU - Patel, Devin
AU - Mohler, James L.
AU - Chen, Ronald C.
AU - Paskett, Electra D.
AU - Liu, Heshan
AU - Peil, Elizabeth S.
AU - Rock, Cheryl L.
AU - Hahn, Olwen
AU - Taylor, John
AU - Van Veldhuizen, Peter J.
AU - Small, Eric J.
AU - Morris, Michael J.
AU - Naughton, Michelle J.
AU - Pierce, John P.
AU - Marshall, James
N1 - Funding Information:
Funding/Support and role of the sponsor: Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under the award number UG1CA189823 (Alliance for Clinical Trials in Oncology NCORP grant), UG1CA233327, UG1CA233290, UG1CA233331, UG1CA233191, U10CA180888 (SWOG), National Cancer Institute 1R01 CA132951-01A1, Department of Defense PC073412, support to Alliance for Clinical Trials in Oncology listed at https://acknowledgements.alliancefound.org , the Prostate Cancer Foundation, and William Hamilton. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Publisher Copyright:
© 2022 European Association of Urology
PY - 2022/11
Y1 - 2022/11
N2 - Background: Health-related quality of life (HRQoL) among patients with localized prostate cancer (PC) on active surveillance (AS) and whether it may be improved through lifestyle-focused interventions remain underdefined. Objective: To assess longitudinal changes in HRQoL in patients who received and those who did not receive a behavioral intervention that increased vegetable intake. Design, setting, and participants: A secondary analysis of participants in the Men's Eating and Living (MEAL) study (Cancer and Leukemia Group 70807 [Alliance]), a randomized trial of vegetable consumption in patients on AS, was conducted. Outcome measurements and statistical analysis: Patient-reported outcomes (PROs) included the Memorial Anxiety Scale for Prostate Cancer (MAX-PC), the Expanded Prostate Cancer Index Composite 26 (EPIC-26), and the Functional Assessment of Cancer Therapy Scale—Prostate (FACT-P). Areas under the curves (AUCs) were used to summarize serial HRQoL. Results and limitations: PROs were completed in 87% (n = 387) of the intention-to-collect population. Baseline characteristics of patients completing HRQoL measures did not differ significantly from the entire study population or between groups. Baseline scores were high for all PROs and remained stable over 24 mo, with no significant differences from baseline at any time point. In adjusted analyses, there were no significant differences in summary AUC measures comparing control with intervention for the total MAX-PC score (p = 0.173); EPIC-26 domains of urinary incontinence (p = 0.210), urinary obstruction (p = 0.062), bowel health (p = 0.607), sexual health (p = 0.398), and vitality (p = 0.363); and total FACT-P scores (p = 0.471). Conclusions: Among men with localized PC on AS enrolled in a randomized trial, HRQoL was high across multiple domains at baseline, remained high during follow-up, and did not change in response to a behavioral intervention that increased vegetable intake. Patient summary: Patients with localized prostate cancer enrolled on active surveillance experience minimal cancer-associated anxiety, suffer low levels of cancer-associated symptoms, and perceive high physical and emotional well-being.
AB - Background: Health-related quality of life (HRQoL) among patients with localized prostate cancer (PC) on active surveillance (AS) and whether it may be improved through lifestyle-focused interventions remain underdefined. Objective: To assess longitudinal changes in HRQoL in patients who received and those who did not receive a behavioral intervention that increased vegetable intake. Design, setting, and participants: A secondary analysis of participants in the Men's Eating and Living (MEAL) study (Cancer and Leukemia Group 70807 [Alliance]), a randomized trial of vegetable consumption in patients on AS, was conducted. Outcome measurements and statistical analysis: Patient-reported outcomes (PROs) included the Memorial Anxiety Scale for Prostate Cancer (MAX-PC), the Expanded Prostate Cancer Index Composite 26 (EPIC-26), and the Functional Assessment of Cancer Therapy Scale—Prostate (FACT-P). Areas under the curves (AUCs) were used to summarize serial HRQoL. Results and limitations: PROs were completed in 87% (n = 387) of the intention-to-collect population. Baseline characteristics of patients completing HRQoL measures did not differ significantly from the entire study population or between groups. Baseline scores were high for all PROs and remained stable over 24 mo, with no significant differences from baseline at any time point. In adjusted analyses, there were no significant differences in summary AUC measures comparing control with intervention for the total MAX-PC score (p = 0.173); EPIC-26 domains of urinary incontinence (p = 0.210), urinary obstruction (p = 0.062), bowel health (p = 0.607), sexual health (p = 0.398), and vitality (p = 0.363); and total FACT-P scores (p = 0.471). Conclusions: Among men with localized PC on AS enrolled in a randomized trial, HRQoL was high across multiple domains at baseline, remained high during follow-up, and did not change in response to a behavioral intervention that increased vegetable intake. Patient summary: Patients with localized prostate cancer enrolled on active surveillance experience minimal cancer-associated anxiety, suffer low levels of cancer-associated symptoms, and perceive high physical and emotional well-being.
KW - Cancer prevention
KW - Health-related quality of life
KW - Prostate cancer
UR - http://www.scopus.com/inward/record.url?scp=85132634935&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85132634935&partnerID=8YFLogxK
U2 - 10.1016/j.euf.2022.03.007
DO - 10.1016/j.euf.2022.03.007
M3 - Article
C2 - 35504836
AN - SCOPUS:85132634935
SN - 2405-4569
VL - 8
SP - 1607
EP - 1616
JO - European Urology Focus
JF - European Urology Focus
IS - 6
ER -